NRX Pharmaceuticals (STU:B1Q) Beginning Cash Position : €4.23 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Beginning Cash Position?

NRX Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2024 was €4.23 Mil.

NRX Pharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2023 (€14.03 Mil) to Dec. 2023 (€8.16 Mil) and declined from Dec. 2023 (€8.16 Mil) to Mar. 2024 (€4.23 Mil).

NRX Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2021 (€1.64 Mil) to Dec. 2022 (€26.06 Mil) but then declined from Dec. 2022 (€26.06 Mil) to Dec. 2023 (€18.39 Mil).

NRX Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for NRX Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Beginning Cash Position Chart

NRX Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

0.72

1.64

26.06

18.39

NRX Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial											18.73	15.23	14.03	8.16	4.23

NRX Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

NRX Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals (STU:B1Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines